Predict Prostate风险沟通工具在初诊非转移性前列腺癌患者中的临床影响:多中心随机对照试验
这项多中心随机对照试验纳入145例初诊非转移性前列腺癌患者,评估Predict Prostate在线个体化风险沟通工具对决策的影响。结果显示,使用该工具的患者决策冲突评分降低26%(16.1 vs 21.7,p=0.027),对15年前列腺癌特异性死亡率和总生存获益的感知更准确(p<0.001),且超过90%认为有用、94%愿意推荐。
要点
- Predict Prostate工具可降低非转移性前列腺癌患者的决策冲突和不确定性。
- 工具使患者对长期生存预后的感知更现实、更准确。
- 焦虑评分和最终治疗选择在两组间无显著差异。
核心结论
- Predict Prostate减少决策冲突和不确定性,并使患者对预后的感知更现实。
研究设计与样本
- 多中心随机对照试验,在英国8个中心纳入145例初诊非转移性前列腺癌患者,中位年龄67岁(IQR 61-72),PSA 6.8 ng/ml(IQR 5.1-8.8)。
主要发现
- Predict Prostate组平均决策冲突量表评分为16.1,标准治疗组为21.7,降低26%(p=0.027)。
- 支持、不确定性和价值清晰度三个子量表评分均 favoring Predict Prostate(均p<0.05)。
- 两组焦虑评分和最终治疗选择无显著差异。
- Predict Prostate组对15年前列腺癌特异性死亡率和根治性治疗总生存获益的感知显著更低且更准确(p<0.001)。
- 57%的男性报告Predict Prostate对前列腺癌特异性死亡率的估计低于预期,36%报告更不可能选择根治性治疗;超过90%认为有用,94%愿意推荐。
临床怎么用
- 可将Predict Prostate工具用于初诊非转移性前列腺癌患者的决策沟通,以降低决策冲突并纠正对预后的过高估计。
局限性
- 未来需要更大规模的试验来检验其对最终治疗决策的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Predict Prostate is a freely available online personalised risk communication tool for men with nonmetastatic prostate cancer. Its accuracy has been assessed in multiple validation studies, but its clinical impact among patients has not hitherto been assessed. OBJECTIVE: To assess the impact of the tool on patient decision-making and disease perception. DESIGN, SETTING, AND PARTICIPANTS: A multicentre randomised controlled trial was performed across eight UK centres among newly diagnosed men considering either active surveillance or radical treatment. A total of 145 patients were included between 2018 and 2020, with median age 67 yr (interquartile range [IQR] 61-72) and prostate-specific antigen 6.8 ng/ml (IQR 5.1-8.8). INTERVENTION: Participants were randomised to either standard of care (SOC) information or SOC and a structured presentation of the Predict Prostate tool. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Validated questionnaires were completed by assessing the impact of the tool on decisional conflict, uncertainty, anxiety, and perception of survival. RESULTS AND LIMITATIONS: Mean Decisional Conflict Scale scores were 26% lower in the Predict Prostate group (mean = 16.1) than in the SOC group (mean = 21.7; p = 0.027). Scores on the "support", "uncertainty", and "value clarity" subscales all favoured Predict Prostate (all p < 0.05). There was no significant difference in anxiety scores or final treatment selection between the two groups. Patient perception of 15-yr prostate cancer-specific mortality (PCSM) and overall survival benefit from radical treatment were considerably lower and more accurate among men in the Predict Prostate group (p < 0.001). In total, 57% of men reported that the Predict Prostate estimates for PCSM were lower than expected, and 36% reported being less likely to select radical treatment. Over 90% of patients in the intervention group found it useful and 94% would recommend it to others. CONCLUSIONS: Predict Prostate reduces decisional conflict and uncertainty, and shifts patient perception around prognosis to be more realistic. This randomised trial demonstrates that Predict Prostate can directly inform the complex decision-making process in prostate cancer and is felt to be useful by patients. Future larger trials are warranted to test its impact upon final treatment decisions. PATIENT SUMMARY: In this national study, we assessed the impact of an individualised risk communication tool, called Predict Prostate, on patient decision-making after a diagnosis of localised prostate cancer. Men were randomly assigned to two groups, which received either standard counselling and information, or this in addition to a structured presentation of the Predict Prostate tool. Men who saw the tool were less conflicted and uncertain in their decision-making, and recommended the tool highly. Those who saw the tool had more realistic perception about their long-term survival and the potential impact of treatment upon this. TAKE HOME MESSAGE: The use of an individualised risk communication tool, such as Predict Prostate, reduces patient decisional conflict and uncertainty when deciding about treatment for nonmetastatic prostate cancer. The tool leads to more realistic perceptions about survival outcomes and prognosis.
引用
- Thurtle D, Jenkins V, Freeman A, et al. Clinical Impact of the Predict Prostate Risk Communication Tool in Men Newly Diagnosed with Nonmetastatic Prostate Cancer: A Multicentre Randomised Controlled Trial. Eur Urol. 2021. PMID: 34493413. doi:10.1016/j.eururo.2021.08.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。